Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiostatin-endostatin gene therapy Oxford BioMedica (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms GEM
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 06 Apr 2017 Last checked against ClinicalTrial.gov.
    • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 05 May 2015 According to an Oxford BioMedica media release, results from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top